Nova Leah announces acquisition of Fresenius Medical Care as a customer
Nova Leah, the Dundalk headquartered medical device security company, has announced a significant global customer win.
Fresenius Medical Care, a provider of dialysis products and services, which reported revenues of US$17.9bn in 2016, has selected and will implement Nova Leah’s cybersecurity risk management tool Select Evidence.
Select Evidence is the world’s first expert cybersecurity risk management system for connected medical devices.
Nova Leah recently announced the creation of 78 jobs in Dundalk. It is initially targeting customers in the imaging and electro medical device sectors in the US, a market that is estimated to be worth $155bn of which connected devices account for approximately $51bn.
Fresenius Medical Care meanwhile employs over 100,000 people worldwide and cares for more than 300,000 patients in its global network of over 3,600 dialysis clinics.
According to a report in The Irish Independent, the German company operates over 30 production sites worldwide to provide products such as dialysis machines and dialyzers.
SelectEvidence is designed to guide medical device manufacturers implementing cybersecurity requirements and best practices over the lifetime of devices in compliance with US FDA (Food & Drug Administration) recommendations during premarket and post market activities.